跳至主要内容
临床试验/ACTRN12611000657921
ACTRN12611000657921已完成未知

Week-Week and Month-Month Biological Variation and Reference Change Values of NTproBNP in the Stable Dialysis Population

Princess Alexandra Hospital0 个研究点目标入组 50 人开始时间: 2011年6月28日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • In-centre haemo- or peritoneal dialysis patients established on a single dialysis modality for at least 90-days
  • Stable dialysis prescription for at least one month
  • Aged 18-years or older
  • Able to provide informed consent
  • Echocardiogram within 12-months of enrollment

排除标准

  • Living renal transplantation planned within 5-months of enrolment.
  • Home haemodialysis
  • Patients on peritoneal dialysis not receiving continuous therapy (e.g. NIPD).
  • Permanent pacemaker and/or implantable cardiac defibrillator.
  • Joint replacements, orthopaedic pins, mechanical heart valves and amputations.
  • Any of the following events / conditions in the month prior to screening:
  • Admission to hospital for any cause.
  • Change in dry body weight target of > 1kg.
  • Unscheduled haemodialysis for treatment of hypertension, dyspnoea or congestive cardiac failure.
  • Change in dialysis prescription.
  • Initiation or dose alteration of angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, or aldosterone receptor antagonist.
  • If has ischaemic heart disease – change in severity of angina – increased frequency and/or occurrence with lesser degrees of exertion and/or alteration in dose of anti-anginal agent(s).
  • If has arrhythmia – change in dose of anti-arrhythmic agent or initiation of new anti-arrhythmic agent.
  • Systemic infection.
  • Congenital heart disease (excluding haemodynamically insignificant patent foramen ovale).
  • Documented severe left ventricular systolic dysfunction defined as an ejection fraction less than 30% by Simpson’s rule.
  • Severe aortic stenosis or regurgitation.
  • Severe mitral stenosis or regurgitation.
  • Severe pulmonary hypertension (RVSP > [60 mmHg > RA]) due to any cause.
  • ST or non-ST segment myocardial infarction (defined as a combination of serial elevation in Troponin T and any one of new ST/T wave changes on ECG and/or symptoms of cardiac ischaemia) in the 6-months prior to screening.
  • Cardiac surgery and/or coronary angioplasty in the 6-months prior to screening.
  • Pulmonary embolism in the preceding 6-months.
  • Advanced malignancy.
  • Current immunosuppressive pharmacotherapy for any indication.

研究者

相似试验